NewAmsterdam Pharma Company N.V. (NAMSW) Operating cash flow 2021–2025
NewAmsterdam Pharma Company N.V. (NAMSW) annual operating cash flow history from SEC filings — net cash provided by operating activities each fiscal year.
-$147.8MFY2025 · since FY2021: -$29.5M → -$147.8M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$147.8M | +6.8% |
| FY2024 | -$158.6M | -12.3% |
| FY2023 | -$141.2M | -1424.1% |
| FY2022 | $10.7M | +136.1% |
| FY2021 | -$29.5M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More NAMSW financial trends
NAMSW RevenueNAMSW Net incomeNAMSW Net marginNAMSW Gross profitNAMSW Gross marginNAMSW Operating incomeNAMSW Operating marginNAMSW Free cash flowNAMSW Capital expendituresNAMSW Return on equityNAMSW Stock buybacksNAMSW Dividends paidNAMSW Total assetsNAMSW Total liabilitiesNAMSW Shareholders’ equityNAMSW overview →